Evidence map›Paper›PMID 27279607›Full record

ArticleJournal of virology2016

Role of Conserved E2 Residue W420 in Receptor Binding and Hepatitis C Virus Infection.

Vanessa M Cowton, Allan G N Angus, Sarah J Cole, Christina K Markopoulou, Ania Owsianka, James I Dunlop, Deborah E Gardner, Thomas Krey, Arvind H Patel

Open access · bronzeAbstract read
In one paragraph

Article in Journal of virology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.6field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 17 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Global mapping of antibody recognition of the hepatitis C virus E2 glycoprotein: Implications for vaccine design.Proceedings of the National Academy of Sciences of the United States of America · 2016
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 3 countries.

Vanessa M CowtonMRC-University of Glasgow Centre for Virus Research, Garscube Campus, Glasgow, United Kingdom.
Allan G N AngusMRC-University of Glasgow Centre for Virus Research, Garscube Campus, Glasgow, United Kingdom.
Sarah J ColeMRC-University of Glasgow Centre for Virus Research, Garscube Campus, Glasgow, United Kingdom.
Christina K MarkopoulouMRC-University of Glasgow Centre for Virus Research, Garscube Campus, Glasgow, United Kingdom.
Ania OwsiankaMRC-University of Glasgow Centre for Virus Research, Garscube Campus, Glasgow, United Kingdom.
James I DunlopMRC-University of Glasgow Centre for Virus Research, Garscube Campus, Glasgow, United Kingdom.
Deborah E GardnerMRC-University of Glasgow Centre for Virus Research, Garscube Campus, Glasgow, United Kingdom.
Thomas KreyInstitut Pasteur, Unité de Virologie Structurale, Department Virologie, Paris, France.
Arvind H PatelMRC-University of Glasgow Centre for Virus Research, Garscube Campus, Glasgow, United Kingdom arvind.patel@glasgow.ac.uk.
MRC University of Glasgow Centre for Virus Research · GBInstitut Pasteur · FR

Funding

Medical Research Council MC_U130184144Medical Research Council MC_UU_12014/2
6 · The paper itself

Abstract

unlabelledHepatitis C virus (HCV) enters cells via interactions with several host factors, a key one being that between the viral E2 envelope glycoprotein and the CD81 receptor. We previously identified E2 tryptophan residue 420 (W420) as an essential CD81-binding residue. However, the importance of W420 in the context of the native virion is unknown, as those previous studies predate the infectious HCV cell culture (cell culture-derived HCV [HCVcc]) system. Here, we introduced four separate mutations (F, Y, A, or R) at position 420 within the infectious HCVcc JFH-1 genome and characterized their effects on the viral life cycle. While all mutations reduced E2-CD81 binding, only two (W420A and W420R) reduced HCVcc infectivity. Further analyses of mutants with hydrophobic residues (F or Y) found that interactions with the receptors SR-BI and CD81 were modulated, which in turn determined the viral uptake route. Both mutant viruses were significantly less dependent on SR-BI, and its lipid transfer activity, for virus entry. Furthermore, these viruses were resistant to the drug erlotinib, which targets epidermal growth factor receptor (EGFR) (a host cofactor for HCV entry) and also blocks SR-BI-dependent high-density lipoprotein (HDL)-mediated enhancement of virus entry. Together, our data indicate a model where an alteration at position 420 causes a subtle change in the E2 conformation that prevents interaction with SR-BI and increases accessibility to the CD81-binding site, in turn favoring a particular internalization route. These results further show that a hydrophobic residue with a strong preference for tryptophan at position 420 is important, both functionally and structurally, to provide an additional hydrophobic anchor to stabilize the E2-CD81 interaction. IMPORTANCE: Hepatitis C virus (HCV) is a leading cause of liver disease, causing up to 500,000 deaths annually. The first step in the viral life cycle is the entry process. This study investigates the role of a highly conserved residue, tryptophan residue 420, of the viral glycoprotein E2 in this process. We analyzed the effect of changing this residue in the virus and confirmed that this region is important for binding to the CD81 receptor. Furthermore, alteration of this residue modulated interactions with the SR-BI receptor, and changes to these key interactions were found to affect the virus internalization route involving the host cofactor EGFR. Our results also show that the nature of the amino acid at this position is important functionally and structurally to provide an anchor point to stabilize the E2-CD81 interaction.

Indexed as

Virus AttachmentAmino AcidsAmino Acid SubstitutionCell LineDNA Mutational AnalysisHepacivirusHumansModels, BiologicalMutagenesis, Site-DirectedScavenger Receptors, Class BTetraspanin 28Viral Envelope ProteinsVirus InternalizationAmino AcidsCD81 protein, humanglycoprotein E2, Hepatitis C virusSCARB1 protein, humanScavenger Receptors, Class BTetraspanin 28Viral Envelope Proteins

Identifiers

PMID27279607
PMCPMC4984626
OpenAlexW2414142839

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.